Status:
COMPLETED
Theta Burst Stimulation for Compulsive Behavior Non-invasive Brain Stimulation Study
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Compulsive Behavior
Obsessive-Compulsive Disorder
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
This project seeks to identify causal neural mechanisms underlying unwanted, repetitive behaviors (compulsions). Using non-invasive brain stimulation coupled with practice in a computer task, we will ...
Eligibility Criteria
Inclusion
- Participants will:
- Be between the ages of 18 and 55 years
- Endorse problematic compulsive behaviors, per self-report and clinician-administered measures.
- Agree to video taping of structured clinical interview
- Report that they will reside in the Pittsburgh area for at least 5 weeks
Exclusion
- Failure to meet standard MRI inclusion criteria: those who endorse claustrophobia, those who have cardiac pacemakers, neural pacemakers, surgical clips in the brain or blood vessels, surgically implanted metal plates, screws or pins, cochlear implants, implanted uterine devices, metal braces, or other metal objects in their body, especially in the eye. Dental fillings do not present a problem. Plastic or removable dental appliances do not require exclusion. History of significant injury or surgery to the brain or spinal cord that would impair interpretation of results. Pregnancy, determined by pregnancy tests on females.
- Medical contraindications for Transcranial Magnetic Stimulation (TMS):
- Presence of a neurologic disorder or medication therapy known to alter seizure threshold (e.g., stroke, aneurysm, brain surgery, structural brain lesion, brain injury, frequent/severe headaches)
- Recurrent seizures or epilepsy in participant or family history of hereditary epilepsy
- Pregnancy
- Metallic implants in body or other devices that may be affected by magnetic field
- Significant heart disease or cerebrovascular disease
- Medications with seizure threshold lowering potential, e.g., clomipramine, Monoamine Oxidase inhibitors (MAOi's), imipramine, clozapine
- Acute suicidality or other psychiatric crises requiring treatment escalation
- Changes made to treatment regimen within 4 weeks of baseline assessment
- Reading level \<6th grade
- Presence of bipolar, psychotic, autism spectrum, or substance use disorder (i.e. current use of mood altering drugs such as cocaine, cannabis or marijuana, opiates, amphetamines, and barbiturates)
- Presence of movement disorder or tics affecting manual responses
- Inability to read text from 2 feet away (corrective lenses allowed)
Key Trial Info
Start Date :
September 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2020
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT03265015
Start Date
September 15 2017
End Date
March 30 2020
Last Update
August 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania, United States, 15213